Study of Edoxaban in adults with nephrotic syndrome
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests how the blood thinner edoxaban works in people with nephrotic syndrome, a kidney condition that raises clot risk. It compares results with healthy volunteers to see if the drug is safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have nephrotic syndrome with heavy protein in urine and low blood albumin (below 30 g/L)
- Your kidney function (creatinine clearance) is above 50 mL/min
- You weigh more than 60 kg and your BMI is between 18.5 and 28 kg/m²
- You have no recent bleeding problems, stroke, or heart failure, and are not on certain other blood thinners or interacting medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the blood thinner edoxaban to standard aspirin or clopidogrel therapy can better prevent another stroke in adults aged 75 and older who had a recent ischemic stroke and are in normal heart rhythm.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
This trial tests if a lower dose of the blood thinner edoxaban can safely prevent another stroke in very elderly patients (80+) who have both atrial fibrillation and a past stroke or mini-stroke. It focuses on those with extra bleeding risks due to low weight, reduced kidney function, previous bleeds, or certain other medications.
This early-stage study compares how your body responds to an enoxaparin biosimilar (a new version of a blood thinner) versus the original brand Clexane. Researchers want to confirm the new version works the same way and is safe in healthy adults.
This trial tests how a blood thinner called enoxaparin works in intensive care patients with kidney problems, including those on a kidney replacement therapy (CVVH). The goal is to see if the drug prevents clots safely in these patients.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.